Trial Profile
Active-Control, Multicenter, Randomized, Open-Label, Safety And Efficacy Study Evaluating The Use Of Apixaban In The Treatment Of Symptomatic Deep Vein Thrombosis And Pulmonary Embolism In Japanese
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Sep 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Heparin; Warfarin
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Adverse reactions; Registrational
- Acronyms AMPLIFY-J
- Sponsors Pfizer
- 12 Sep 2016 Results of this and two other trial (AMPLIFY and AMPLIFY-EXT) published in the Drugs (2016).
- 10 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.